Novavax Expands Matrix-M Adjuvant Deals Through Partnership With Sanofi
Novavax, Inc. of Gaithersburg, Maryland is continuing to move away from relying primarily on direct vaccine sales and is instead focusing more heavily on licensing agreements and corporate partnerships. The company recently expanded deals with pharmaceutical giants Pfizer, Inc. and Sanofi SA as it attempts to build a more stable revenue stream following a sharp […]
Novavax Signs Licensing Agreement With Pfizer for Vaccine Adjuvant Technology
Novavax, Inc. and Pfizer, Inc. have signed a licensing arrangement allowing Pfizer access to Novavax’s Matrix-M adjuvant technology to boost immune response to vaccines. The agreement will allow for use in vaccines targeting up to two infectious diseases.1 Novavax’s Matrix-M technology is an aluminum-free adjuvant designed to enhance the immune response in protein-based vaccines such […]
Government Buys 1.5 Million More Doses of Novavax’s COVID Vaccine
Biotechnology company Novavax announced that it has made a modification to an existing contract with the U.S. Department of Health and Human Services (HHS) and the Department of Defense (DoD) to provide up to 1.5 million more doses of its Nuvaxovid COVID-19 vaccine (also known as “NVX-CoV2373” and “Covovax”), in addition to the 3.2 million […]
Novavax’s Protein COVID-19 Vaccine Now Available in Europe
Novavax’s experimental NVX-CoV2373 (also known as “Nuvaxovid” and “Covovax”) COVID-19 vaccine has been authorized for distribution in the European Union (E.U.), making it the fifth COVID vaccine available for use in the E.U. Approved for people over 18 years old, Nuvaxoid is the first protein subunit COVID vaccine to be approved for use.1 2 The […]
Moderna, Novavax Developing Combined Single-Dose COVID-19 and Influenza Vaccine
American pharmaceutical and biotechnology company Moderna, Inc., which partnered with the U.S. National Institutes of Allergy and Infectious Diseases (NIAID) to develop an mRNA COVID-19 vaccine being distributed in the United States under an Emergency Use Authorization (EUA) announced that it is developing a combined single-dose booster vaccine for COVID-19 and seasonal influenza.1 In a […]